Smith & Nephew (NYSE:SNN) yesterday released results from a trial of its Pico negative-pressure wound therapy system used in orthopedic surgeries, touting reductions in wound exudate distributions, dressing changes and hospital stays.
The 220-patient randomized, controlled trial was carried out over 12 months at the U.K.’s Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust comparing the Pico system with standard dressings on closed surgical incisions.
Data from the study indicated a reduction in the probability of experiencing excessing lengths of stay with use of the Pico system when compared to standard dressing, with the average stay being between 1 and 10 days with the Pico as compared to between 2 and 61 with standard dressings.
“By introducing Pico as a prophylactic measure we have been able to demonstrate predictable wound healing following total hip and knee replacement procedures. Better wound management offers significant value to our hospital both in terms of reducing associated healthcare costs and by improving each patient’s outcome and experience,” lead author Sudheer Karlakki of RJAH said in a press release.
Smith & Nephew touted a 4-fold reduction in the number of patients experiencing grade 4 distribution of wind exudate within the dressinc compared to standard wound dressing for patients undergoing joint replacement.
Results indicated a 6% decrease in superficial surgical site complications, as well as a significant reduction in the total number of dressing changes for patients treated with the Pico system, Smith & Nephew said.
“Wound complications do not only impact the hospital, but they can have a devastating effect on a patient’s recovery. There is often a financial impact for the family as more time off work is required, not just for the patient but also their carer. High levels of wound exudate or infections can also cause embarrassment and discomfort, often resulting in significant anxiety. PICO can help prevent these issues through improved wound healing and increased patient confidence,” Helen Griffiths of RJAH said in a prepared release.
In July, Smith & Nephew said a New York hospital was the 1st to use its new robotics-assisted total knee replacement system following its 510(k) clearance from the FDA.
The surgery took place at the John T. Mather Memorial Hospital in Port Jefferson, N.Y., involving Smith & Nephew’s handheld robotics-assisted Navio platform, and its Journey II BCS knee implant.
Navio provides surgeons a robotics-assisted hand piece, navigation and cut guides specific to Navio that are designed to enable better outcomes. Additionally, the system relies on software that incorporates 3D surface capture to predict elements such as joint laxity and help make precise implant positioning possible. Patients don’t need a preoperative CT scan, either, unlike other robotics-assisted platforms, Smith & Nephew said.